Financials data is unavailable for this security.
View more
Year on year TG Therapeutics Inc grew revenues 8,290.02% from 2.79m to 233.66m while net income improved from a loss of 198.34m to a gain of 12.67m.
| Gross margin | 88.32% |
|---|---|
| Net profit margin | -5.42% |
| Operating margin | -0.19% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, cash reserves at TG Therapeutics Inc fell by 9.36m. Cash Flow from Financing totalled 72.71m or 31.12% of revenues. In addition the company used 31.41m for operations while cash used for investing totalled 50.65m.
| Cash flow per share | -0.1192 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in USDView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
